BioPortUSA, announced today the opening of a European office in Stuttgart, Germany to better serve the needs of life science companies, including med-tech, biotech, and pharmaceutical, who have expressed an interest in entering the US marketplace. The office will be managed by Dr. Manfred Kauer.
Manfred has over 24 years experience working in the healthcare industry, focused on Innovation Management, Entrepreneurship, Oncology, Molecular Biology, and Biotechnology. Beginning his career as a Post Doctoral Research Associate at the Max Delbrück Center in Berlin and Ulm University, he established research groups to investigate the role of chromosome translocations in cancer development and molecular analysis of the role of transcription factors in cell models.
In March 1997, Manfred was Senior Scientist at the Deutsches Diabetes Forschungsinstitut, where he established quantitative methods for gene expression analysis and array fabrication. As Scientist Development Molecular Diagnostics at Variom Biotechnology AG in 2001, Manfred established new biochip detection systems for diagnosis of human hereditary disease profiles and genetic predispositions.
From August 2001 to December 2005, Manfred served as Senior Scientist und Project Manager Microarray Technology at Scienion, a manufacturer of cutting-edge miniaturisation devices for pharma and biotech applications. He then joined BioRegio STERN Management, a non-profit association for the support of life science businesses in greater Stuttgart region where he oversaw regional marketing, economic development and public relations for the cluster. His worked encompassed consultation with entrepreneurs, founders, scientists, and political stakeholders in Europe and the United States.
In the past, Manfred was Department Director at the University of Hohenheim in Stuttgart, Germany, overseeing research promotion, technology transfer and start-up activities.
Manfred holds Bachelor and Masters degrees in Biology from the University Konstanz in Marburg, Germany and a PhD in Tumor Biology from the Institute for Molecular Biology and Tumor Research from Philipps University in Marburg, Germany.
Dr. Kauer’s focus will be primarily on supporting life science companies from Germany, Austria, and Switzerland who either are interested in expanding their operations into the US market or may already have a base of operation in America but can benefit from the extensive service offering of BioPortUSA to grow their business.
BioPortUSA simplifies the U.S. market entry process and helps foreign companies navigate the changing FDA regulatory environment, as well as the legal, tax, immigration and commercialization requirements that they will face in establishing a U.S. business presence. By engaging BioPortUSA, client companies access a menu of core professional services all in one place that will enable them to correctly determine their early investment and accelerate the commercialization process for their product lines.
Related Post
Social Media
Latest Articles
Sep 23, 2024, 11:19 AM
Aug 13, 2024, 12:35 PM
May 23, 2024, 10:13 AM
Featured entries
